Multivariable analysis for event-free survival
| Variable . | P . | Relative hazard ratio ± SE . | Confidence interval . |
|---|---|---|---|
| <.001 | |||
| Clofarabine treatment | .037 | 0.83 ± 0.08 | 0.69-0.99 |
| Age | <.001 | 1.03 ± 0.0 | 1.02-1.03 |
| White blood cell count | <.001 | 1.17 ± 0.04 | 1.10-1.25 |
| ELN intermediate risk I | <.001 | 2.10 ± 0.30 | 1.59-2.78 |
| ELN intermediate risk II | <.001 | 1.95 ± 0.30 | 1.45-2.63 |
| ELN adverse risk | <.001 | 3.99 ± 060 | 2.97-5.35 |
| Secondary AML | .0072 | 1.49 ± 0.22 | 1.11-1.98 |
| Treatment-related AML | .91 | 1.02 ± 022 | 0.68-1.55 |
| Variable . | P . | Relative hazard ratio ± SE . | Confidence interval . |
|---|---|---|---|
| <.001 | |||
| Clofarabine treatment | .037 | 0.83 ± 0.08 | 0.69-0.99 |
| Age | <.001 | 1.03 ± 0.0 | 1.02-1.03 |
| White blood cell count | <.001 | 1.17 ± 0.04 | 1.10-1.25 |
| ELN intermediate risk I | <.001 | 2.10 ± 0.30 | 1.59-2.78 |
| ELN intermediate risk II | <.001 | 1.95 ± 0.30 | 1.45-2.63 |
| ELN adverse risk | <.001 | 3.99 ± 060 | 2.97-5.35 |
| Secondary AML | .0072 | 1.49 ± 0.22 | 1.11-1.98 |
| Treatment-related AML | .91 | 1.02 ± 022 | 0.68-1.55 |
Result for the multivariable Cox regression for EFS. The following covariates were considered: patient age, white blood cell count at diagnosis (log transformation), ELN risk category 2010 (values expressed in relation to ELN favorable),12 secondary and treatment-related AML (in relation to AML de novo). ELN risk 2010 defined according to Döhner et al12 but slightly modified for bi-allelic CEBPA gene mutations, as detailed in the supplemental Appendix.